It is exciting to note that there are already regulatory cell death-related drug applications, such as Venetoclax (132), a selective Bcl-2 inhibitor in acute myelogenous leukemia, chronic lymphocytic leukemia, and small lymphocytic lymphoma. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.